Bicara Therapeutics Inc.
Bicara Therapeutics Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 9, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 39.8 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 9, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| October 31, 2027 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Trial Milestone | Phase 1 |
| March 15, 2028 | A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC | Trial Milestone | Phase 2 |
| April 15, 2028 | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Trial Milestone | Phase 2/Phase 3 |
Track BCAX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open BCAX in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 25, 2026 | 8-K filed: Material agreement | Corporate | — |
| August 11, 2026 | Quarterly results filed (8-K) | Earnings | — |
| July 28, 2026 | 8-K filed: Leadership change, Reg FD disclosure | Corporate | — |
| May 21, 2026 | 8-K filed: Other event | Filing | — |
| May 11, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 30, 2026 | Quarterly results filed (8-K) | Earnings | — |
| February 26, 2026 | Quarterly results filed (8-K) | Earnings | — |
| February 19, 2026 | 8-K filed: Other event | Filing | — |
| January 12, 2026 | 8-K filed: Other event | Filing | — |
| December 8, 2025 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| November 10, 2025 | Quarterly results filed (8-K) | Earnings | — |
| August 12, 2025 | Quarterly results filed (8-K) | Earnings | — |
| June 6, 2025 | 8-K filed: Material agreement | Corporate | — |
| May 13, 2025 | Quarterly results filed (8-K) | Earnings | — |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.